

# Indinavir sulfate

**Brand Name:** Crixivan

## Drug Description

Indinavir sulfate, the salt form of the active drug indinavir, is a synthetic antiretroviral agent and a peptidomimetic protease inhibitor. [1]

## HIV/AIDS-Related Uses

Indinavir sulfate was approved by the FDA on March 13, 1996, for use in combination with other antiretroviral agents or as monotherapy for the treatment of HIV infection.[2] Evidence suggests that use of a three-drug regimen that includes indinavir and two nucleoside reverse transcriptase inhibitors (NRTIs) can increase CD4 cell counts and decrease plasma HIV-1 RNA levels in pediatric patients who previously received long-term therapy with nucleoside reverse transcriptase inhibitors, especially if the three-drug regimen includes NRTIs not used in previous regimens.[3]

Indinavir sulfate is also used in conjunction with other antiretroviral agents for postexposure prophylaxis of HIV infection in healthcare workers and others who have had occupational exposure to HIV.[4]

## Pharmacology

Indinavir is a selective, competitive, reversible inhibitor of HIV protease, an enzyme that plays an essential role in HIV replication and the formation of infectious virus. Indinavir is a structural analogue of the HIV Phe-Pro protease cleavage site. The drug's structure inhibits the function of HIV protease, blocking virus maturation and causing the formation of immature, noninfectious virions. Indinavir is active in both acutely and chronically infected cells; chronically infected cells are not affected by nucleoside reverse transcriptase inhibitors (NRTIs). While indinavir does not affect early stages of the HIV replication cycle, it does interfere with the production of infectious HIV, limiting further infectious spread of the virus.[5] Indinavir is active against HIV-1 and HIV-2.[6]

Indinavir is rapidly absorbed from the GI tract, with peak plasma concentrations of the drug generally occurring in less than 1 hour and averaging 0.8

hours in fasting adults. Presence of food in the GI tract can substantially decrease the extent of absorption of oral indinavir.[7]

Distribution of indinavir into body tissues and fluids has not been fully characterized. Indinavir has been detected in low concentrations in the cerebrospinal fluid of adults or children receiving the drug.[8]

Indinavir sulfate is in FDA Pregnancy Category C. Adequate and well-controlled studies have not been done in pregnant women. It is not known whether indinavir crosses the placenta in humans; it does cross the placenta in laboratory animals. Hyperbilirubinemia has occurred in patients receiving indinavir sulfate, but it is unknown whether drug administered during pregnancy will exacerbate hyperbilirubinemia in neonates.[9] Indinavir sulfate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. An Antiretroviral Pregnancy Registry has been established to monitor the outcomes of pregnant women exposed to indinavir. Physicians may register patients by calling 1-800-258-4263. Although it is not known whether indinavir is excreted in human milk, there exists the potential for adverse effects from indinavir in nursing infants. Mothers should be instructed to discontinue nursing if they are receiving indinavir.[10]

Protein binding of indinavir is moderate and approximately 60% over a range of 0.05 to 10 mcg/ml.[11]

The metabolic fate of indinavir has not been fully determined, but the drug is metabolized in the liver. Systemic clearance of indinavir is rapid; the plasma half-life of indinavir averages 1.8 hours in adults and 1.1 hours in children. Indinavir is metabolized to at least seven metabolites, including one glucuronide conjugate and six oxidative metabolites. In vitro studies indicate that cytochrome P450 enzyme CYP3A4 is the major enzyme involved in the formation of the oxidative metabolites. Indinavir is excreted primarily in the feces both as unabsorbed drug and as metabolites. Following a 400 mg oral dose, 83% was recovered

# Indinavir sulfate



## **Pharmacology (cont.)**

---

in feces (19.1% as unchanged drug) and 19% was recovered in urine (9.4% as unchanged drug). It is not known if indinavir is removed by hemodialysis or peritoneal dialysis.[12]

Although the complete mechanisms of resistance or reduced susceptibility to indinavir have not been fully determined to date, acquisition of multiple HIV protease mutations appears to be necessary for high-level resistance to the drug. In vitro studies indicate that the antiretroviral effects of indinavir and some NRTIs are additive or synergistic against HIV-1, and there is evidence from clinical studies that antiretroviral regimens that include indinavir and one or two nucleoside agents can suppress in vivo viral replication to a greater extent than monotherapy. There is also evidence that use of regimens that suppress HIV replication to levels that cannot be detected by sensitive plasma HIV-1 RNA assays is associated with a lower viral mutation rate and may delay or prevent the emergence of resistance. Several studies indicate that the incidence of HIV protease mutations and HIV reverse transcriptase mutations associated with indinavir or zidovudine resistance, respectively, is lower in isolates obtained from patients receiving indinavir/zidovudine combination therapy than in isolates obtained from patients receiving monotherapy with these drugs.[13]

Some degree of cross-resistance can occur among the various protease inhibitors (PIs). Further study is needed to more fully evaluate the extent and clinical implications of cross-resistance among the drugs and to determine whether administration of one PI has any effect on subsequent therapy with any other PI.[14] Cross-resistance between indinavir and reverse transcriptase inhibitors is thought to be unlikely because they affect different enzyme target sites; however, cross-resistance was observed between indinavir and ritonavir, another PI. Varying degrees of resistance have been noted between indinavir and other PIs.[15] [16]

## **Adverse Events/Toxicity**

---

Adverse effects commonly observed with indinavir use include nephrolithiasis/urolithiasis, diabetes or hyperglycemia, asthenia, GI disturbances

(abdominal or stomach pain, nausea, diarrhea, vomiting), headache, insomnia, taste perversion, dizziness, and somnolence.[17]

The most frequently clinically reported serious adverse effect of indinavir sulfate is nephrolithiasis/urolithiasis. This effect appears to be dose related, occurring more frequently in patients receiving more than 2.4 grams daily and is significantly more frequent in pediatric patients. If symptoms of nephrolithiasis/urolithiasis (flank pain with or without hematuria) occur, temporary interruption or discontinuation of indinavir sulfate therapy may be considered.[18] To ensure adequate hydration, which reduces the risk of developing nephrolithiasis, the manufacturer recommends that adults receiving indinavir sulfate drink at least 1.5 liters of water per day.[19]

Some patients receiving indinavir sulfate have developed acute hemolytic anemia, with some cases resulting in death. Hepatitis, including cases resulting in hepatic failure and death, has been reported in patients treated with indinavir, though a causal relationship between indinavir use and these events has not been established. Administration of PIs such as indinavir may cause new onset of diabetes mellitus or exacerbation of pre-existing diabetes mellitus and hyperglycemia, but a causal relationship has not been established between PI therapy and these events.[20]

## **Drug and Food Interactions**

---

Presence of food in the GI tract substantially decreases absorption of indinavir. In clinical studies, administration with a meal high in calories, fat, and protein resulted in a 77% ± 8% AUC reduction and an 84% ± 7% reduction in peak plasma concentration. Administration with lighter meals resulted in little or no change in the indinavir AUC, peak plasma concentration, or trough concentration.[21] For optimum absorption, indinavir should be administered with water 1 hour before or 2 hours after a meal.[22]

Both indinavir and atazanavir are associated with indirect hyperbilirubinemia. Combinations of these drugs have not been adequately studied and coadministration of indinavir and atazanavir is not recommended.[23] Delavirdine inhibits the

# Indinavir sulfate

## Drug and Food Interactions (cont.)

metabolism of indinavir such that coadministration of 400 mg or 600 mg indinavir three times daily with 400 mg delavirdine three times daily alters indinavir AUC, C<sub>max</sub>, and C<sub>min</sub>. Conversely, indinavir had no effect on delavirdine pharmacokinetics.[24] In a small, volunteer-based study, twice-daily coadministration of 800 mg indinavir with ritonavir with food for two weeks resulted in a 2.7-fold increase in daily indinavir AUC, 1.6-fold increase in indinavir C<sub>max</sub>, and an 11-fold increase in indinavir C<sub>min</sub> for a 100 mg ritonavir dose. With a 200 mg ritonavir dose, there was a 3.6-fold increase of daily indinavir AUC, a 1.8-fold increase in indinavir C<sub>max</sub>, and a 24-fold increase in indinavir C<sub>min</sub>. In the same study, twice-daily coadministration of indinavir with ritonavir (100 or 200 mg) resulted in daily ritonavir AUC increases not observed in people who received the same doses of ritonavir alone.[25]

If both didanosine and indinavir are part of a treatment regimen, they should be administered at least 1 hour apart on an empty stomach. A normal acidic pH may be necessary for the optimal absorption of indinavir, and didanosine requires a buffer to increase the pH so that acid does not rapidly degrade didanosine in the stomach.[26]

Competition of cytochrome P450 CYP3A4 substrates by indinavir could inhibit the metabolism of astemizole, cispride, midazolam, terfenadine, and triazolam, resulting in elevated plasma concentrations of these medications. Thus, concurrent administration with indinavir raises the potential for serious and/or life threatening side effects. Concurrent use of ketoconazole and indinavir results in a 68% increase in the AUC of indinavir; a dosage reduction of indinavir to 600 mg every 8 hours is recommended when these medications are coadministered.[27]

Concurrent use of rifabutin and indinavir results in a 32% increase in the AUC of indinavir and a 204% in the AUC of rifabutin. Dosage reduction of rifabutin to 400 mg every 8 hours is necessary when it is coadministered with indinavir. Because rifampin is a potent inducer of CYP3A4, which could significantly decrease the plasma concentration of indinavir, concurrent use with

indinavir is not recommended.[28]

Concomitant use of indinavir with lovastatin or simvastatin is not recommended. Caution should be used when any PIs, including indinavir, are used concurrently with other HMG-CoA reductase inhibitors (atorvastatin or cerivastatin). The risk of myopathy or rhabdomyolysis may be increased when PIs are used with these drugs.[29] Concomitant use of indinavir and St. John's wort (*Hypericum perforatum*) or products containing St. John's wort may substantially decrease indinavir concentrations and may lead to loss of virologic response and possible resistance to indinavir or other PIs.[30]

Coadministration of indinavir and sildenafil, tadalafil, or vardenafil is expected to substantially increase sildenafil, tadalafil, or vardenafil plasma concentrations and the risk of phosphodiesterase type 5 (PDE) inhibitor-associated adverse effects, including hypotension, visual changes, and priapism. Patients receiving a PDE5 inhibitor should report any symptoms to their doctors.[31] Indinavir (800 mg every 8 hours) coadministered with a single 10-mg dose of vardenafil results in a 16-fold increase in vardenafil AUC, a sevenfold increase in vardenafil C<sub>max</sub>, and a twofold increase in vardenafil half-life.[32]

In vitro drug metabolism studies suggest that there is a potential for drug interactions when trazodone is given with CYP3A4 inhibitors. It is likely that indinavir, a CYP3A4 inhibitor, may lead to substantial increases in trazodone plasma concentrations with the potential for adverse effects. If trazodone is used with a potent CYP3A4 inhibitor, a lower dose of trazodone should be considered.[33]

Coadministration of indinavir and efavirenz reduces indinavir levels. Clinical data suggest that when indinavir is used in combination with efavirenz, increasing the dosage of indinavir to 1000 mg once every 8 hours is not sufficient to compensate for this drug interaction. In a 10-day study investigating indinavir 1000 mg administered every 8 hours with efavirenz, the indinavir AUC decreased 33% to 46% and the C<sub>min</sub> decreased 39% to 57%. The addition of ritonavir 100 to 200 mg twice daily may help to boost concentrations of

# ***Indinavir sulfate***



## **Drug and Food Interactions (cont.)**

indinavir when coadministered with efavirenz, but data on the optimal dosage is not available.[34]

## **Contraindications**

Indinavir sulfate is contraindicated in patients with clinically significant hypersensitivity to indinavir or any of its components.[35]

## **Clinical Trials**

For information on clinical trials that involve Indinavir sulfate, visit the ClinicalTrials.gov web site at <http://www.clinicaltrials.gov>. In the Search box, enter: Indinavir sulfate AND HIV Infections.

## **Dosing Information**

Mode of Delivery: Oral.[36]

Dosage Form: Capsules containing 100, 200, 333, and 400 mg of indinavir.[37] [38]

The recommended dosage of indinavir is 800 mg (usually two 400 mg capsules) every 8 hours. In patients with mild to moderate hepatic insufficiency due to cirrhosis, the dose of indinavir should be reduced to 600 mg every 8 hours. The Crixivan prescribing information details specific dosing adjustments when indinavir is coadministered with delavirdine, didanosine, efavirenz, itraconazole, ketoconazole, and rifabutin.[39]

Storage: Store in a tightly closed container at room temperature, 15 C to 30 C (59 F to 86 F). Indinavir sulfate capsules are sensitive to moisture and should be dispensed and stored in the original container with a desiccant. Store unit-dose packages at 15 C to 30 C (59 F to 86 F). Protect from moisture.[40]

## **Chemistry**

CAS Name:

# Indinavir sulfate



## Chemistry (cont.)

CAS Number: 157810-81-6 (indinavir sulfate)[42]

150378-17-9 (indinavir)[43]

Molecular formula: C<sub>36</sub>H<sub>47</sub>N<sub>5</sub>O<sub>4</sub>.H<sub>2</sub>SO<sub>4</sub>[44]

C60.74%, H6.94%, N9.84%, O17.98%, S4.50%[45]

Molecular weight: 711.88[46]

Melting point: 150 to 153 C[47]

Physical Description: Indinavir sulfate is a white to off-white, hygroscopic, crystalline powder.[48]

Solubility: Very soluble in water and in methanol.[49]

## Other Names

L-735,524[50]

MK-639[51]

IDV[52]

## Further Reading

Burger DM, Aarnoutse RE, Dieleman JP, Gyssens IC, Nouwen J, de Marie S, Koopmans PP, Stek M Jr, van der Ende ME. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study). *Antivir Ther.* 2003 Oct;8(5):455-61. PMID: 14640393

Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW. A review of low-dose ritonavir in protease inhibitor combination therapy. *Clin Infect Dis.* 2003 Jun 15;36(12):1585-92. Epub 2003 Jun 05. Review. PMID: 12802760

Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW; AIDS Clinical Trials Group 398 Study Team. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: A randomized trial. *JAMA.* 2002 Jul

# Indinavir sulfate



## **Further Reading (cont.)**

---

10;288(2):169-80.

Hirsch MS, Steigbigel RT, Staszewski S, McMahon D, Fischl MA, Hirschel B, Squires K, DiNubile MJ, Harvey CM, Chen J, Leavitt RY; Protocol 039 Study Group. Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection. *Clin Infect Dis.* 2003 Oct 15;37(8):1119-24. Epub 2003 Sep 18. PMID: 14523778

Rayner CR, Galbraith KJ, Marriott JL, Duncan GJ. A critical evaluation of the therapeutic range of indinavir. *Ann Pharmacother.* 2002 Jul-Aug;36(7-8):1230-7. Review. PMID: 12086558

## **Manufacturer Information**

---

Indinavir sulfate  
Merck & Company, Inc  
One Merck Dr  
P.O. Box 100  
Whitehouse Station, NJ 08889-0100  
18006094618

Crixivan  
Merck & Company, Inc  
One Merck Dr  
P.O. Box 100  
Whitehouse Station, NJ 08889-0100  
18006094618

## **For More Information**

---

Contact your doctor or an AIDSinfo Health Information Specialist:

- Via Phone: 1-800-448-0440 Monday - Friday, 12:00 p.m. (Noon) - 5:00 p.m. ET
- Via Live Help: [http://aidsinfo.nih.gov/live\\_help](http://aidsinfo.nih.gov/live_help) Monday - Friday, 12:00 p.m. (Noon) - 4:00 p.m. ET

## **References**

---

# Indinavir sulfate



1. AHFS Drug Information - 2003; p. 665
2. USP DI - 2003; p. 1535
3. AHFS Drug Information - 2003; p. 658
4. AHFS Drug Information - 2003; p. 658
5. AHFS Drug Information - 2003; p. 663
6. USP DI - 2003; p. 1535
7. AHFS Drug Information - 2003; p. 664
8. AHFS Drug Information - 2003; p. 664
9. USP DI - 2003; p. 1536
10. Merck & Company - Crixivan Prescribing Information, January 2003, p. 15. Available at: <http://www.crixivan.com/crixivan/shared/documents/pi.pdf>. Accessed 06/14/04.
11. AHFS Drug Information - 2003; p. 664
12. AHFS Drug Information - 2003; p. 664-665
13. AHFS Drug Information - 2003; p. 663-664
14. AHFS Drug Information - 2003; p. 664-665
15. AHFS Drug Information - 2003; p. 663-664
16. USP DI - 2003; p. 1534
17. USP DI - 2003; p. 1536
18. Merck & Company - Crixivan Prescribing Information, January 2003, pp. 11, 16. Available at: <http://www.crixivan.com/crixivan/shared/documents/pi.pdf>. Accessed 06/14/04.
19. Merck & Company - Crixivan Prescribing Information, January 2003, p. 19. Available at: <http://www.crixivan.com/crixivan/shared/documents/pi.pdf>. Accessed 06/14/04.
20. Merck & Company - Crixivan Prescribing Information, January 2003, pp. 11, 16. Available at: <http://www.crixivan.com/crixivan/shared/documents/pi.pdf>. Accessed 06/14/04.
21. Merck & Company - Crixivan Prescribing Information, January 2003, p. 2. Available at: <http://www.crixivan.com/crixivan/shared/documents/pi.pdf>. Accessed 06/14/04.
22. Merck & Company - Crixivan Prescribing Information, January 2003, p. 19. Available at: <http://www.crixivan.com/crixivan/shared/documents/pi.pdf>. Accessed 06/14/04.
23. FDA - Crixivan Capsules Prescribing Information, 2004, p. 20. Available at: [http://www.fda.gov/cder/foi/label/2004/20685slr046\\_047\\_crixivan\\_lbl.pdf](http://www.fda.gov/cder/foi/label/2004/20685slr046_047_crixivan_lbl.pdf). Accessed 05/13/04.
24. FDA - Crixivan Capsules Prescribing Information, 2004, p.9. Available at: [http://www.fda.gov/cder/foi/label/2004/20685slr046\\_047\\_crixivan\\_lbl.pdf](http://www.fda.gov/cder/foi/label/2004/20685slr046_047_crixivan_lbl.pdf). Accessed 05/13/04.
25. FDA - Crixivan Capsules Prescribing Information, 2004, p. 9-10. Available at: [http://www.fda.gov/cder/foi/label/2004/20685slr046\\_047\\_crixivan\\_lbl.pdf](http://www.fda.gov/cder/foi/label/2004/20685slr046_047_crixivan_lbl.pdf). Accessed 05/13/04.
26. USP DI - 2003; p. 1535
27. USP DI - 2003; p. 1536
28. USP DI - 2003; p. 1536
29. FDA - Crixivan Capsules Prescribing Information, 2004, p. 17-18. Available at: [http://www.fda.gov/cder/foi/label/2004/20685slr046\\_047\\_crixivan\\_lbl.pdf](http://www.fda.gov/cder/foi/label/2004/20685slr046_047_crixivan_lbl.pdf). Accessed 05/13/04.
30. FDA - Crixivan Capsules Prescribing Information, 2004, p.18. Available at: [http://www.fda.gov/cder/foi/label/2004/20685slr046\\_047\\_crixivan\\_lbl.pdf](http://www.fda.gov/cder/foi/label/2004/20685slr046_047_crixivan_lbl.pdf). Accessed 05/13/04.

# Indinavir sulfate



31. FDA - Crixivan Capsules Prescribing Information, 2004, p.18. Available at: [http://www.fda.gov/cder/foi/label/2004/20685slr046\\_047\\_crixivan\\_lbl.pdf](http://www.fda.gov/cder/foi/label/2004/20685slr046_047_crixivan_lbl.pdf). Accessed 05/13/04.
32. FDA - Crixivan Capsules Prescribing Information, 2004, p.10. Available at: [http://www.fda.gov/cder/foi/label/2004/20685slr046\\_047\\_crixivan\\_lbl.pdf](http://www.fda.gov/cder/foi/label/2004/20685slr046_047_crixivan_lbl.pdf). Accessed 05/13/04.
33. FDA - Desyrel Prescribing Information. Available at: [http://www.fda.gov/medwatch/SAFETY/2004/Desyrel\\_PI.pdf](http://www.fda.gov/medwatch/SAFETY/2004/Desyrel_PI.pdf). Accessed 05/24/04.
34. FDA - Sustiva Prescribing Information, June 2003. Available at: [http://www.fda.gov/cder/foi/label/2003/20972slr021\\_21360slr005\\_sustiva\\_lbl.pdf](http://www.fda.gov/cder/foi/label/2003/20972slr021_21360slr005_sustiva_lbl.pdf). Accessed 07/07/04.
35. Merck & Company - Crixivan Prescribing Information, January 2003, p. 11. Available at: <http://www.crixivan.com/crixivan/shared/documents/pi.pdf>. Accessed 06/14/04.
36. Merck & Company - Crixivan Prescribing Information, January 2003, p. 19. Available at: <http://www.crixivan.com/crixivan/shared/documents/pi.pdf>. Accessed 06/14/04.
37. Merck & Company - Crixivan Prescribing Information, January 2003, pp. 19-20. Available at: <http://www.crixivan.com/crixivan/shared/documents/pi.pdf>. Accessed 06/14/04.
38. AHFS Drug Information - 2003; p. 665
39. AHFS Drug Information - 2003; p. 658
40. Merck & Company - Crixivan Prescribing Information, January 2003, p. 20. Available at: <http://www.crixivan.com/crixivan/shared/documents/pi.pdf>. Accessed 06/14/04.
41. ChemIDplus - Available at: <http://chem.sis.nlm.nih.gov/chemidplus/>. Accessed 06/14/04.
42. ChemIDplus - Available at: <http://chem.sis.nlm.nih.gov/chemidplus/>. Accessed 06/14/04.
43. ChemIDplus - Available at: <http://chem.sis.nlm.nih.gov/chemidplus/>. Accessed 06/14/04.
44. ChemIDplus. - Available at: <http://chem.sis.nlm.nih.gov/chemidplus/>. Accessed 06/14/04.
45. Calculation. -
46. Merck Index - 2001; p. 889
47. Merck Index - 2001; p. 889
48. Merck & Company - Crixivan Prescribing Information, January 2003, p. 1. Available at: <http://www.crixivan.com/crixivan/shared/documents/pi.pdf>. Accessed 06/14/04.
49. Merck & Company - Crixivan Prescribing Information, January 2003, p. 1. Available at: <http://www.crixivan.com/crixivan/shared/documents/pi.pdf>. Accessed 06/14/04.
50. ChemIDplus - Available at: <http://chem.sis.nlm.nih.gov/chemidplus/>. Accessed 06/14/04.
51. ChemIDplus - Available at: <http://chem.sis.nlm.nih.gov/chemidplus/>. Accessed 06/14/04.
52. ChemIDplus - Available at: <http://chem.sis.nlm.nih.gov/chemidplus/>. Accessed 06/14/04.